Beyond the Role of CD55 As a Complement Component

Overview

Journal Immune Netw

Specialty Allergy & Immunology

Date 2018 Mar 6

PMID 29503741

Citations 48

Authors

So Hee Dho

Jae Cheong Lim

Lark Kyun Kim

Affiliations

Soon will be listed here.

Abstract

The complement is a part of the immune system that plays several roles in removing pathogens. Despite the importance of the complement system, the exact role of each component has been overlooked because the complement system was thought to be a nonspecific humoral immune mechanism that worked against pathogens. Decay-accelerating factor (DAF or CD55) is a known inhibitor of the complement system and has recently attracted substantial attention due to its role in various diseases, such as cancer, protein-losing enteropathy, and malaria. Some protein-losing enteropathy cases are caused by CD55 deficiency, which leads to complement hyperactivation, malabsorption, and angiopathic thrombosis. In addition, CD55 has been reported to be an essential host receptor for infection by the malaria parasite. Moreover, CD55 is a ligand of the seven-span transmembrane receptor CD97. Since CD55 is present in various cells, the functional role of CD55 has been expanded by showing that CD55 is associated with a variety of diseases, including cancer, malaria, protein-losing enteropathy, paroxysmal nocturnal hemoglobinuria, and autoimmune diseases. This review summarizes the current understanding of CD55 and the role of CD55 in these diseases. It also provides insight into the development of novel drugs for the diagnosis and treatment of diseases associated with CD55.

Citing Articles

Investigating the impact of Premolis semirufa caterpillar bristle toxins on human chondrocyte activation and inflammation.

de Lima C, Pohl P, Villas-Boas I, Pidde G, Tambourgi D PLoS Negl Trop Dis. 2025; 19(2):e0012816.

PMID: 39928679 PMC: 11809898. DOI: 10.1371/journal.pntd.0012816.

Respiratory extracellular vesicle isolation optimization through proteomic profiling of equine samples and identification of candidates for cell-of-origin studies.

Hickman E, Carberry V, Carberry C, Cooper B, Mordant A, Mills A PLoS One. 2025; 20(1):e0315743.

PMID: 39854355 PMC: 11760557. DOI: 10.1371/journal.pone.0315743.

CD2 expressing innate lymphoid and T cells are critical effectors of immunopathogenesis in hidradenitis suppurativa.

Kashyap M, Mishra B, Sinha R, Jin L, Gou Y, Kumar N Proc Natl Acad Sci U S A. 2024; 121(48):e2409274121.

PMID: 39560648 PMC: 11621750. DOI: 10.1073/pnas.2409274121.

Combinatorial effector targeting (COMET) for transcriptional modulation and locus-specific biochemistry.

Wilson C, Pommier G, Richman D, Sambold N, Hussmann J, Weissman J bioRxiv. 2024; .

PMID: 39554033 PMC: 11565746. DOI: 10.1101/2024.10.28.620517.

A Histological Analysis and Detection of Complement Regulatory Protein CD55 in SARS-CoV-2 Infected Lungs.

Silawal S, Gogele C, Pelikan P, Werner C, Levidou G, Mahato R Life (Basel). 2024; 14(9).

PMID: 39337843 PMC: 11432792. DOI: 10.3390/life14091058.

References

Huser A, Rudolph M, Hofmann C . Incorporation of decay-accelerating factor into the baculovirus envelope generates complement-resistant gene transfer vectors. Nat Biotechnol. 2001; 19(5):451-5. DOI: 10.1038/88122. View

Lin H, Stacey M, Saxby C, Knott V, Chaudhry Y, Evans D . Molecular analysis of the epidermal growth factor-like short consensus repeat domain-mediated protein-protein interactions: dissection of the CD97-CD55 complex. J Biol Chem. 2001; 276(26):24160-9. DOI: 10.1074/jbc.M101770200. View

Nakagawa M, Mizuno M, Kawada M, Uesu T, Nasu J, Takeuchi K . Polymorphic expression of decay-accelerating factor in human colorectal cancer. J Gastroenterol Hepatol. 2001; 16(2):184-9. DOI: 10.1046/j.1440-1746.2001.02418.x. View

Thurman J, Nester C . All Things Complement. Clin J Am Soc Nephrol. 2016; 11(10):1856-1866. PMC: 5053787. DOI: 10.2215/CJN.01710216. View

Hamann J, Wishaupt J, van Lier R, Smeets T, Breedveld F, Tak P . Expression of the activation antigen CD97 and its ligand CD55 in rheumatoid synovial tissue. Arthritis Rheum. 1999; 42(4):650-8. DOI: 10.1002/1529-0131(199904)42:4<650::AID-ANR7>3.0.CO;2-S. View

Kolev M, Towner L, Donev R . Complement in cancer and cancer immunotherapy. Arch Immunol Ther Exp (Warsz). 2011; 59(6):407-19. DOI: 10.1007/s00005-011-0146-x. View

He Z, Wu H, Jiao Y, Zheng J . Expression and prognostic value of CD97 and its ligand CD55 in pancreatic cancer. Oncol Lett. 2015; 9(2):793-797. PMC: 4301556. DOI: 10.3892/ol.2014.2751. View

Meng Z, Liu M, Hong H, Du Q, Chen Y . Expression and prognostic value of soluble CD97 and its ligand CD55 in intrahepatic cholangiocarcinoma. Tumour Biol. 2017; 39(3):1010428317694319. DOI: 10.1177/1010428317694319. View

Gorter A, Blok V, Haasnoot W, Ensink N, Daha M, Fleuren G . Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis. Lab Invest. 1996; 74(6):1039-49. View

10.

Mustafa T, Klonisch T, Hombach-Klonisch S, Kehlen A, Schmutzler C, Koehrle J . Expression of CD97 and CD55 in human medullary thyroid carcinomas. Int J Oncol. 2004; 24(2):285-94. View

11.

Egan E, Jiang R, Moechtar M, Barteneva N, Weekes M, Nobre L . Malaria. A forward genetic screen identifies erythrocyte CD55 as essential for Plasmodium falciparum invasion. Science. 2015; 348(6235):711-4. PMC: 4465434. DOI: 10.1126/science.aaa3526. View

12.

Angeletti A, Marasa M, Cravedi P . CD55 Deficiency and Protein-Losing Enteropathy. N Engl J Med. 2017; 377(15):1499. DOI: 10.1056/NEJMc1710011. View

13.

Gao L, Guo S, Cai Y, Gu P, Su Y, Gong H . Cooperation of decay-accelerating factor and membrane cofactor protein in regulating survival of human cervical cancer cells. BMC Cancer. 2009; 9:384. PMC: 2774863. DOI: 10.1186/1471-2407-9-384. View

14.

Han S, Xu C, Wu X, Li J, Liu Z, Zeng Q . The impact of expressions of CD97 and its ligand CD55 at the invasion front on prognosis of rectal adenocarcinoma. Int J Colorectal Dis. 2010; 25(6):695-702. DOI: 10.1007/s00384-010-0926-5. View

15.

Li L, Spendlove I, Morgan J, Durrant L . CD55 is over-expressed in the tumour environment. Br J Cancer. 2001; 84(1):80-6. PMC: 2363604. DOI: 10.1054/bjoc.2000.1570. View

16.

Kim D, Song W . Membrane complement regulatory proteins. Clin Immunol. 2005; 118(2-3):127-36. DOI: 10.1016/j.clim.2005.10.014. View

17.

Ozen A, Comrie W, Ardy R, Conde C, Dalgic B, Beser O . CD55 Deficiency, Early-Onset Protein-Losing Enteropathy, and Thrombosis. N Engl J Med. 2017; 377(1):52-61. PMC: 6690356. DOI: 10.1056/NEJMoa1615887. View

18.

Madjd Z, Durrant L, Bradley R, Spendlove I, Ellis I, Pinder S . Loss of CD55 is associated with aggressive breast tumors. Clin Cancer Res. 2004; 10(8):2797-803. DOI: 10.1158/1078-0432.ccr-1073-03. View

19.

Reis E, Mastellos D, Ricklin D, Mantovani A, Lambris J . Complement in cancer: untangling an intricate relationship. Nat Rev Immunol. 2017; 18(1):5-18. PMC: 5816344. DOI: 10.1038/nri.2017.97. View

20.

Hoffmann E . Inhibition of complement by a substance isolated from human erythrocytes. II. Studies on the site and mechanism of action. Immunochemistry. 1969; 6(3):405-19. DOI: 10.1016/0019-2791(69)90297-3. View